PaperPlayer medrxiv infectious diseases: Recent Episodes
PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.09.09.22279773v1?rss=1
Authors: Das, S., Taylor, K., Kozubek, J., Sardell, J., Gardner, S.
Abstract: Background: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating chronic disease that lacks known pathogenesis, distinctive diagnostic criteria, and effective treatment options. Understanding the genetic (and other) risk factors associated with the disease would begin to help alleviate some of these issues for patients. Methods: We applied both GWAS and the PrecisionLife combinatorial analytics platform to analyze ME/CFS cohorts from UK Biobank, including the Pain Questionnaire cohort, in a case-control design with 1,000 cycles of fully random permutation. The results from this study were supported by a series of replication and cohort comparison experiments, including use of a disjoint Verbal Interview cohort also derived from UK Biobank, and results compared for reproducibility. Results: Combinatorial analysis revealed 199 SNPs mapping to 14 genes, that were significantly associated with 91% of the cases in the ME/CFS population. These SNPs were found to stratify by shared cases into 15 clusters (communities) made up of 84 high-order combinations of between 3-5 SNPs. p-values for these communities range from 2.3 x 10-10 to 1.6 x 10-72. Many of the genes identified are linked to the key cellular mechanisms hypothesized to underpin ME/CFS, including vulnerabilities to stress and/or infection, mitochondrial dysfunction, sleep disturbance and autoimmune development. We noted similarities with genes associated with multiple sclerosis and long COVID, which share some symptoms and potentially a viral infection trigger with ME/CFS. Conclusions: This study provides the first detailed genetic insights into the pathophysiological mechanisms underpinning ME/CFS and offers new approaches for better diagnosis and treatment of patients.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.09.09.22279426v1?rss=1
Authors: Rosa Duque, J. S., Leung, D., Yip, K. M., Lee, D. H. L., So, H.-k., Wong, W. H. S., Lau, Y. L.
Abstract: Background: Vaccine effectiveness (VE) of BNT162b2 and CoronaVac against COVID-19-associated hospitalization and moderate-to-severe disease due to SARS-CoV-2 Omicron BA.2 for pediatric populations that had low exposure to prior SARS-CoV-2 variants needs to be further clarified. This can be studied from the 1.36 million vaccine doses had been administered to 766,601 of 953,400 children and adolescents in Hong Kong (HK) since March 2021 to April 2022. Methods: Using an ecological design leveraging the HK vaccination coverage statistics and public hospital records, this study investigated the VE for children aged 3-11 years and adolescents aged 12-18 years at the population level during the Omicron BA.2 wave from January to April 2022. Findings: VE against COVID-19-associated hospitalization for children was 65.3% for 1 dose of BNT162b2 and 13.0% and 86.1% for 1 and 2 doses of CoronaVac, respectively. For adolescents, VE against COVID-19-associated hospitalization was 60.2% and 82.4% after 1 and 2 doses of BNT162b2 and 30.8% and 90.7% after 1 and 2 doses of CoronaVac, respectively. Protection against moderate-to-severe disease for aged 3-18 was high, with VE of 93.1% and 95.8% after 2 doses of BNT162b2 and CoronaVac, respectively. No COVID-19-associated hospitalization or moderate-to-severe disease occurred for 68,565 children and adolescents who received their third dose. Estimated hospitalizations of children and adolescents averted by vaccination were 68 and 999, respectively, and were 45 and 147 for moderate-to-severe cases. Conclusions: BNT162b2 or CoronaVac provide substantial protection from COVID-19-associated hospitalization and moderate-to-severe disease due to a SARS-CoV-2 variant of concern. Funding: The Providence Foundation.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.09.06.22279633v1?rss=1
Authors: Gener, A. R.
Abstract: Our ability to track the spread of the human monkeypox virus (hMPXV) during the ongoing monkeypox (hMPX) outbreak of 2022 relies on the availability of high-quality reference genomes. However, the way the information content of these genomes is organized in genome databases leaves room for interpretation. A current limitation of hMPXV genomic analysis is that the variability occurring in the inverted terminal repeats (ITRs) cannot be effectively resolved. This is because of shortcomings of the leading short-read sequencing and reference-guided assembly and variant calling used in the ongoing global hMPXV outbreak surveillance effort. Here I propose ITR tail-trimming, a simple no-cost reframing of how we organize hMPXV reference genomes and future assemblies. This approach is based on long terminal repeat (LTR) tail-trimming, which is a common practice in HIV sequence analysis. The main point of repeat sequence trimming is to remove problematic sequences while paying attention to limitations of mapping and variant calling in remaining repeat-associated (but ideally no longer repetitive) sequence. ITR tail-trimming would neutralize ITRs as distracting features at the read- and assembly-levels, allowing the global community to focus our efforts to track variability across hMPXV genomes.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.09.07.22279689v1?rss=1
Authors: Ilchmann, H., Chen, L., Samy, N., Reichhardt, D., Schmidt, D., Powell, J., Silbernagl, G., Weidenthaler, H., De Moerlooze, L., Chaplin, P. J.
Abstract: While the MVA BN vaccine has been proven protective against smallpox and monkeypox, the long-term immunological persistence or booster effect has not been described. In this set of clinical studies, participants who had never been immunized against smallpox were randomized to receive, 4 weeks apart: 2 placebo vaccinations (PBO group, N=181); 1 MVA BN vaccination followed by placebo(1xMVA group, N=181); or 2 MVA-BN vaccinations (2xMVA group, N=183). In addition, participants with a history of smallpox vaccination received 1 MVA BN booster (HSPX+ group, N=200). The 1xMVA and 2xMVA groups responded with increases in neutralizing antibody (nAb) GMTs at Week 2 (5.1 and 4.8, respectively) that further increased at Week 4 (7.2 and 7.5). Two weeks after the second primary vaccination in the 2xMVA group (at Week 6), nAb GMT peaked (45.6) before stabilizing 2 weeks thereafter (at Week 8) (34.0). In the HSPX+ group, a rapid anamnestic response was observed with a peak nAb GMT at Week 2 (175.1) that was much larger than the peak responses in either of the primary vaccination (1x or 2xMVA) dose groups of smallpox vaccine-naive subjects. Persistence of nAbs relative to baseline was observed at 6 months in all groups (highest in HSPX+), with a return to near baseline nAb levels 2 years later. Subsets of {approx}75 participants each, who received primary vaccinations in the 1xMVA and 2xMVA groups, were administered an MVA BN booster 2 years later. Both booster dose (BD) groups exhibited rapid anamnestic responses with nAb GMTs that peaked 2 weeks post-booster (80.7 and 125.3). These post booster titers in the 1xMVA and 2xMVA groups were higher than those observed at any timepoint following primary vaccination, were comparable to HSPX+ subjects who had been administered a booster, and remained elevated at 6 months post booster (25.6 and 49.3). The observed anamnestic responses, in the absence of sustained detectable nAbs, support the presence of durable immunological memory following MVA BN immunization. No safety concerns were identified, and the most common adverse event following the 2-year MVA BN booster was injection site erythema in 82.2% of participants.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.09.09.22279751v1?rss=1
Authors: Skowronski, D. M., Kaweski, S. E., Irvine, M. A., Kim, S., Chuang, E. S., Sabaiduc, S., Fraser, M., Reyes, R. C., Henry, B., Levett, P. N., Petric, M., Krajden, M., Sekirov, I.
Abstract: Background: We chronicle SARS-CoV-2 sero-prevalence through eight cross-sectional sero-surveys (snapshots) in the Lower Mainland (Greater Vancouver and Fraser Valley), British Columbia, Canada from March 2020 to August 2022. Methods: Anonymized-residual sera were obtained from children and adults attending an outpatient laboratory network. Sera were tested with at least three immuno-assays per snapshot to detect spike (S1) and/or nucleocapsid protein (NP) antibodies. Sero-prevalence was defined by dual-assay positivity, including any or infection-induced, the latter requiring S1+NP antibody detection from January 2021 owing to vaccine availability. Infection-induced estimates were used to assess the extent to which surveillance case reports under-estimated infections. Results: Sero-prevalence was less than or equal to 1% by the 3rd snapshot in September 2020 and less than 5% by January 2021 (4th). Following vaccine roll-out, sero-prevalence increased to greater than 55% by May/June 2021 (5th), ~80% by September/October 2021 (6th), and greater than 95% by March 2022 (7th). In all age groups, infection-induced sero-prevalence remained less than 15% through September/October 2021, increasing through subsequent Omicron waves to ~40% by March 2022 (7th) and ~60% by July/August 2022 (8th). By August 2022, at least 70-80% of children less than or equal to 19 years, 60-70% of adults 20-59 years, but ~40% of adults greater than or equal to 60 years had been infected. Surveillance case reports under-estimated infections by 12-fold between the 6th-7th and 92-fold between the 7th-8th snapshots. Interpretation: By August 2022, most children and adults had acquired SARS-CoV-2 vaccine and infection exposures, resulting in more robust hybrid immunity. Conversely the elderly, still at greatest risk of severe outcomes, remain largely-dependent on vaccine-induced protection alone, and should be prioritized for additional doses.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.09.06.22279552v1?rss=1
Authors: Pilling, O. A., Grace, C. A., Reis-Cunha, J. L., Berry, A. S., Mitchell, M. W., Yu, J. A., Malekshahi, C., Krespan, E., Go, C. K., Lombana, C., Song, Y. S., Amorim, C. F., Lago, A. S., Carvalho, L. P., Carvalho, E. M., Brisson, D., Scott, P., Jeffares, D. C., Beiting, D. P.
Abstract: In Brazil, Leishmania braziliensis is the main causative agent of the neglected tropical disease, cutaneous leishmaniasis (CL). CL caused by L. braziliensis can present on a spectrum of disease severity with high rate of treatment failure. Yet the parasite factors that may contribute to disease presentation and treatment outcome are not well understood, in part because successfully isolating and culturing parasites from patient lesions remains a major technical challenge. Here we describe the development of selective whole genome amplification (SWGA) for Leishmania and show that this method enables culture-independent analysis of parasite genomes obtained directly from primary patient skin samples, allowing us to circumvent artifacts associated with adaptation to culture. We show that SWGA can be applied to multiple Leishmania species residing in different host species, suggesting that this method is broadly useful in both experimental infection models and clinical studies. Finally, we show that parasite genome sequencing data generated by SWGA of skin biopsies collected from patients in Corte de Pedra, Bahia, Brazil exhibit substantial genetic diversity and can be integrated with published whole genome data from parasite isolates to identify variants associated with high treatment failure rates observed in Northeast Brazil.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.09.04.22279574v1?rss=1
Authors: Lamichhane, J., Upreti, M., Nepal, K., Upadhyay, B. P., Maharjan, U., Shrestha, R. K., Chapagain, R. H., Banjara, M. R., Thapa Shrestha, U.
Abstract: Background: Acute Respiratory Tract Infection (ARI) is one of the most common causes of mortality and morbidity worldwide. Every year millions of children suffer from viral Respiratory Tract Infections (RTIs) ranging from mild to severe illnesses. Human Metapneumovirus (HMPV) is among the most frequent viruses responsible for RTIs. However, HMPV infections and their severity among children have not been explored yet in Nepal. Therefore, the study aimed to determine the incidence of HMPV among children attending Kanti Children Hospital and assess the clinical characteristics of the infections as well as find out the co-infections. Methods: A hospital-based cross-sectional study was carried out from September 2018 to April 2019. A total of 105 throat swabs were collected from children clinically suspected of ARIs. The collected samples were tested for the presence of HMPV RNA by Multiplex Real-time PCR (RT-PCR) assay. Results: The incidence of HMPV in children in the Hospital was found to be 13.3%. The HMPV was more prevalent in the age group less than three years (21.8%) which was found to be statistically significant (p - 0.038). Cough and fever were the most common clinical features present in all children infected with HMPV followed by rhinorrhea, sore throat, and wheezing. HMPV positive children were diagnosed with pneumonia (42.9%), bronchiolitis (28.5%), upper respiratory tract infections (14.3%) and asthma (14.3%). The incidence of HMPV was high in late winter (14.3%) followed by early spring (13.5%). Conclusion: This study provides the baseline information on HMPV and associated co-infection with other respiratory viruses for differential diagnosis and rational use of antibiotics in clinical management. Keywords: Respiratory tract infection, Human Metapneumovirus, Multiplex Real-time RT-PCR, Pneumonia, Bronchiolitis
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.09.08.22279729v1?rss=1
Authors: Pietiainen, V., Polso, M., Migh, E., Guckelsberger, C., Harmati, M., Diosdi, A., Turunen, L., Hassinen, A., Potdar, S., Koponen, A., Gyukity-Sebestyen, E., Kovacs, F., Kriston, A., Hollandi, R., Burian, K., Terhes, G., Visnyovszki, A., Fodor, E., Lacza, Z., Kantele, A., Kolehmainen, P., Kakkola, L., Strandin, T., Levanov, L., Kallioniemi, O., Kemeny, L., Julkunen, I., Vapalahti, O., Buzas, K., Paavolainen, L., Horvath, P., Hepojoki, J.
Abstract: Here, we describe a scalable and automated, high-content microscopy-based, mini-immunofluorescence assay (mini-IFA) for serological testing i.e. detection of antibodies. Unlike conventional IFA, which often relies on the use of cells infected with the target pathogen, our assay employs transfected cells expressing individual viral antigens. The assay builds on a custom neural network-based image analysis pipeline for the automated and multiplexed detection of immunoglobulins (IgG, IgA, and IgM) in patient samples. As a proof-of-concept, we employed high-throughput equipment to set up the assay for measuring antibody response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with spike (S), membrane (M), and nucleo (N) protein, and the receptor-binding domain (R) as the antigens. We compared the automated mini-IFA results from hundreds of patient samples to the visual observations of human experts and to the results obtained with conventional ELISA. The comparisons demonstrated a high correlation to both, suggesting high sensitivity and specificity of the mini-IFA. By testing pre-pandemic samples (N=500?) and those collected from patients with RT-PCR confirmed SARS-CoV-2 infection (N=???), we found mini-IFA to be most suitable for IgG and IgA detection. The results demonstrated N and S proteins as the ideal antigens, and the use of these antigens can serve to distinguish between vaccinated and infected individuals. The assay principle described enables detection of antibodies against practically any pathogen, and none of the assay steps require high biosafety level environment. The simultaneous detection of multiple Ig classes allows for distinguishing between recent from past infection.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.09.07.22279662v1?rss=1
Authors: Gould, S., Byrne, R. L., Edwards, T., Aljayyoussi, G., Wooding, D., Buist, K., Kontogianni, K., Bennett, A. M., Atkinson, B., Moore, G., Dunning, J., Todd, S., Hoyle, M.-C., Turtle, L., Solomon, T., Fitzgerald, R., Beadsworth, M., Garner, P., Adams, E. R., Fletcher, T.
Abstract: Background: SARS-CoV-2 nosocomial transmission to patients and healthcare workers (HCWs) has occurred throughout the COVID-19 pandemic. Aerosol generating procedures (AGPs) seemed particularly risky, and policies have restricted their use in all settings. We examined the prevalence of aerosolized SARS-CoV-2 in the rooms of COVID-19 patients requiring AGP or supplemental oxygen compared to those on room air. Methods: Samples were collected prospectively near to adults hospitalised with COVID-19 at two tertiary care hospitals in the UK from November 2020-October 2021. The Sartorius MD8 AirPort air sampler was used to collect air samples at a minimum distance of 1.5 meters from patients. RT-qPCR was used following overnight incubation of membranes in culture media and extraction. Results: We collected 219 samples from patients' rooms: individuals on room air (n=67), receiving oxygen (n=65) or AGP (n=67). Of these, 54 (24.6%) samples were positive for SARS-CoV-2 viral RNA. The highest prevalence was identified in the air around patients receiving oxygen (32.3%, n=21, CI95% 22.2 to 44.3%) with AGP and room air recording prevalence of (20.7%, n=18, CI95% 14.1-33.7%) and (22.3%, n=15, CI95% 13.5-30.4%) respectively. We did not detect a significant difference in the observed frequency of viral RNA between interventions. Interpretation: SARS-CoV-2 viral RNA was detected in the air of hospital rooms of COVID-19 patients, and AGPs did not appear to impact the likelihood of viral RNA. Enhanced respiratory protection and appropriate infection prevention and control measures are required to be fully and carefully implemented for all COVID-19 patients to reduce risk of aerosol transmission.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.09.05.22279174v1?rss=1
Authors: Silal, S. P., Pulliam, J., Meyer-Rath, G., Jamieson, L., Nichols, B., Norman, J., Hounsell, R., Mayet, S., Kagoro, F., Moultrie, H.
Abstract: Background: In March 2020 the South African COVID-19 Modelling Consortium was formed to support government planning for COVID-19 cases and related healthcare. Models were developed jointly by local disease modelling groups to estimate cases, resource needs and deaths due to COVID-19. Methods: The National COVID-19 Epi Model (NCEM) while initially developed as a deterministic compartmental model of SARS-Cov-2 transmission in the nine provinces of South Africa, was adapted several times over the course of the first wave of infection in response to emerging local data and changing needs of government. By the end of the first wave, the NCEM had developed into a stochastic, spatially-explicit compartmental transmission model to estimate the total and reported incidence of COVID-19 across the 52 districts of South Africa. The model adopted a generalised Susceptible-Exposed-Infectious-Removed structure that accounted for the clinical profile of SARS-COV-2 (asymptomatic, mild, severe and critical cases) and avenues of treatment access (outpatient, and hospitalisation in non-ICU and ICU wards). Results: Between end-March and early September 2020, the model was updated several times to generate new sets of projections and scenario analyses to be shared with planners in the national and provincial Departments of Health, the National Treasury and other partners in a variety of formats such as presentations, reports and dashboards. Updates to model structure included finer spatial granularity, limited access to treatment, and the inclusion of behavioural heterogeneity in relation to the adoption of Public Health and Social Measures. These updates were made in response to local data and knowledge and the changing needs of the planners. Conclusions: The NCEM attempted to incorporate a high level of local data to contextualise the model appropriately to address South Africas population and health system characteristics. Origin and contextualisation of data and understanding of the populations interaction with the health system played a vital role in producing and updating estimates of resource needs, demonstrating the importance of harnessing and developing local modelling capacity.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.09.06.22279637v1?rss=1
Authors: Cubas Atienzar, A. I., Byrne, R. L., Aljayyoussi, G., Kontogianni, K., Bengey, D., Clerkin, K., McIntyre, M., Wardale, J., Willams, C. T., Body, R., Escadafal, C., Adams, E. R.
Abstract: Objective: To conduct a head-to-head diagnostic accuracy evaluation of professionally taken anterior nares (AN) and nasopharyngeal (NP) swabs for SARS-CoV-2 antigen detection using rapid diagnostic tests (Ag-RDT). Methods: NP swabs for SARS-CoV-2 reverse transcription quantitative polymerase chain reaction (RT-qPCR) testing and paired AN and NP swabs for the antigen detection were collected from symptomatic participants enrolled at a community drive-through COVID-19 test centre in Liverpool. Two Ag-RDT brands were evaluated: Sure-Status (PMC, India) and Biocredit (RapiGEN, South Korea). The visual read out of the Ag-RDT test band was quantitative scored and the 50% and 95% limit of detection (LoD) of both Ag-RDT brands using AN and NP swabs was calculated using a probabilistic logistic regression model. Results: A total of 604 participants were recruited of which 241 (40.3%) were SARS-CoV-2 positive by RT-qPCR. Sensitivity and specificity of AN swabs was equivalent to the obtained with NP swabs: 83.2% (75.2-89.4%) and 98.8% (96.5-99.6%) utilising NP swabs and 84.0% (76.2-90.1%) and 99.2% (97.0-99.8%) with AN swabs for Sure-Status and; 81.2% (73.1-87.7%) and 99.0% (94.7-86.5%) with NP swabs and 79.5% (71.3-86.3%) and 100% (96.5-100%) with AN swabs for Biocredit. The agreement of the AN and NP swabs was high for both brands with an inter-rater relatability (K) of 0.918 and 0.833 for Sure-Status and Biocredit, respectively. The overall 50% LoD and 95% LoD was 0.9-2.4 x 104 and 3.0-3.2 x 108 RNA copies/mL for NP swabs and 0.3- 1.1 x 105 and 0.7-7.9 x 107 RNA copies/mL and for AN swabs with no significant difference on LoD for any of the swabs types or test brands. Quantitative read-out of test line intensity was more often higher when using NP swabs with significantly higher scores for both Ag-RDT brands. Conclusions: the diagnostic accuracy of the two SARS-CoV-2 Ag-RDTs brands evaluated in this study was equivalent using AN swabs than NP swabs. However, test line intensity was lower when using AN swabs which could influence negatively the interpretation of the Ag-RDT results for lay users. Studies on Ag-RDT self-interpretation using AN and NP swabs are needed to ensure accurate test use in the wider community.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.09.07.22279665v1?rss=1
Authors: Karyakarte, R. P., Das, R., Taji, N., Yanamandra, S., Shende, S., Joshi, S., Karekar, B., Bawale, R., Tiwari, R., Jadhav, M., Sakalkar, S., Chaudhari, G., Rane, S., Agarasen, J., Pillai, P., Dudhate, S., Chandankhede, P., Labhshetwar, R., Gadiyal, Y., Rajmane, M., Mukade, S., Kulkarni, P.
Abstract: Background: The SARS-CoV-2 Omicron variants BA.2.74, BA.2.75 and BA.2.76 have appeared recently in India and have already spread to over 40 countries. They have acquired additional mutations in their spike protein compared to BA.2, branching away on the SARS-CoV-2 phylogenetic tree. These added mutations, over and above those of the parental BA.2 variant, have raised concerns about the impact on viral pathogenicity, transmissibility, and immune evasion properties of the new variants. Material and Methods: A total of 990 RT-PCR positive SARS-CoV-2 samples, with a cycle threshold value (Ct) less than 25, were processed for SARS-CoV-2 whole genome sequencing between 3rd June 2022 to 7th August 2022. All corresponding demographic and clinical data were recorded and analyzed using Microsoft Excel. Results: Out of 990 samples sequenced, BA.2.75 (23.03%) was the predominant Omicron sublineage, followed by BA.2.38 (21.01%), BA.5 (9.70%), BA.2 (9.09%), BA.2.74 (8.89%) and BA.2.76 (5.56%). A total of 228 cases of BA.2.74, BA.2.75 and BA.2.76 were contacted by telephone, of which 215 (94.30%) were symptomatic with mild symptoms, and 13 (5.70%) had no symptoms. Fever (82.02%) was the most common symptom, followed by cough (49.12%), cold (35.97%), fatigue (27.19%), headache (21.05%) and myalgia (20.61%). Of the 228 cases, 195 (85.53%) cases recovered at home, and 33 (14.47%) required institutional quarantine. Recovery with conservative treatment was observed in 92.98% of cases, while 4.83% required additional oxygen therapy. Only 03 (1.32%) cases had poor outcomes resulting in death, and the remaining 225 (98.68%) had a good outcome. Among the 228 cases, 219 (96.05%) cases were vaccinated with COVID-19 vaccine; of these 72.60% had received both doses, 26.03% had also received the precautionary booster dose, while 1.37% were incompletely vaccinated with a single dose of vaccine. Conclusion: The current study indicates that the three BA.2 sublineages are causing mild disease in India. However, BA.2.75 has key mutations that are notable for accelerated growth and transmission and require close and effective monitoring. Keywords: Omicron, BA.2.74, BA.2.75, BA.2.76, SARS-CoV-2 whole-genome sequencing
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.09.07.22278961v1?rss=1
Authors: Szekely, R., Sossen, B., Mukoka, M., Muyoyeta, M., Nakabugo, E., Hella, J., Nguyen, H. V., Ubolyam, S., Chikamatsu, K., Mace, A., Vermeulen, M., Centner, C. M., Nyangu, S., Sanjase, N., Sasamalo, M., Dinh, H. T., Ngo, T. A., Manosuthi, W., Jirajariyavej, S., Mitarai, S., Nguyen, N. V., Avihingsanon, A., Reither, K., Nakiyingi, L., Kerkhoff, A. D., MacPherson, P., Meintjes, G., Denkinger, C. M., Ruhwald, M., FujiLAM Study Consortium
Abstract: Rationale There is an urgent need for rapid, non-sputum point-of-care diagnostics to detect tuberculosis. Objectives This prospective trial in seven high tuberculosis burden countries set out to evaluate the diagnostic accuracy of the point-of-care urine-based lipoarabinomannan assay FUJIFILM SILVAMP TB LAM (FujiLAM) among inpatient and outpatient people living with HIV. Methods Diagnostic performance of FujiLAM at point of care was assessed among adult people with HIV against a mycobacterial reference standard (sputum culture, blood culture, and Xpert Ultra from urine and sputum at enrollment, and additional sputum culture less than or equal to 7 days from enrollment), an extended mycobacterial reference standard including available non-study test results, and a composite reference standard including clinical evaluation. Measurements and Main Results: Of 1624 participants enrolled, 294 (18.0%) were classified as TB positive by extended mycobacterial reference standard. Median age was 40 years, median CD4 cell count was 372 cells/ul, 52% were female and 78% were taking antiretroviral therapy at enrollment. Overall FujiLAM sensitivity was 54.8% (95% CI: 49.1-60.4), and overall specificity was 85.1% (83.1-86.9), against the extended mycobacterial reference standard. Sensitivity and specificity estimates varied between sites, ranging from 26.5% (95% CI: 17.4%-38.0%) to 83.3% (43.6%-97.0%), and 75.0 (65.0%-82.9%) to 96.5 (92.1%-98.5%), respectively. Post-hoc exploratory analysis identified significant variability in the performance of the six FujiLAM lots used in this study. Conclusions Lot variability limited interpretation of FujiLAM test performance. Although the results with the current version of FujiLAM are too variable for clinical decision-making, the lipoarabinomannan biomarker still holds promise for tuberculosis diagnostics.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.09.05.22279589v1?rss=1
Authors: Kaabi, N. A., Yang, Y. K., Liang, Y., Xu, K., Zhang, X. F., Kang, Y., Jin, Y. Q., Hou, J. W., Zhang, J., Yang, T., Hussein, S., ElDein, M. S., Lei, Z. H., Zhang, H., Shao, S., Liu, Z. M., Liu, N., Zheng, X., Su, J. G., Yang, S. S., Cong, X. F., Tan, Y., Lei, W. W., Gao, X. J., Jiang, Z. W., Wang, H., Li, M., Mekki, H. M., Zaher, W., Mahmoud, S., Zhang, X., Qu, C., Liu, D. Y., Zhang, J., Yang, M. J., Eltantawy, I., Xiao, P., Shen, F. J., Wu, J. J., Han, Z. B., Du, L. F., Tang, F., Chen, S., Ma, Z. J., Zheng, F., Hou, Y. N., Li, X. Y., Li, X., Wang, Z. N., Yin, J. L., Mao, X. Y., Zhang, J., Qu
Abstract: BACKGROUND The rising breakthrough infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, especially Omicron and its sub-lineages, have raised an urgent need to develop broad-spectrum vaccines against coronavirus disease 2019 (COVID-19). We have developed a mosaic-type recombinant vaccine candidate, named NVSI-06-09, having immune potentials against a broad range of SARS-CoV-2 variants. METHODS An ongoing randomized, double-blind, controlled phase 2 trial was conducted to evaluate the safety and immunogenicity of NVSI-06-09 as a booster dose in subjects aged 18 years and older from the United Arab Emirates (UAE), who had completed two or three doses of BBIBP-CorV vaccinations at least 6 months prior to the enrollment. The participants were randomly assigned with 1:1 to receive a booster dose of NVSI-06-09 or BBIBP-CorV. The primary outcomes were immunogenicity and safety against SARS-CoV-2 Omicron variant, and the exploratory outcome was cross-immunogenicity against other circulating strains. RESULTS A total of 516 participants received booster vaccination. Interim results showed a similar safety profile between NVSI-06-09 and BBIBP-CorV booster groups, with low incidence of adverse reactions of grade 1 or 2. For immunogenicity, by day 14 after the booster vaccination, the fold rises in neutralizing antibody geometric mean titers (GMTs) from baseline level elicited by NVSI-06-09 were remarkably higher than those by BBIBP-CorV against the prototype strain (19.67 vs 4.47-fold), Omicron BA.1.1 (42.35 vs 3.78-fold), BA.2 (25.09 vs 2.91-fold), BA.4 (22.42 vs 2.69-fold), and BA.5 variants (27.06 vs 4.73-fold). Similarly, the neutralizing GMTs boosted by NVSI-06-09 against Beta and Delta variants were also 6.60-fold and 7.17-fold higher than those boosted by BBIBP-CorV. CONCLUSIONS A booster dose of NVSI-06-09 was well-tolerated and elicited broad-spectrum neutralizing responses against SARS-CoV-2 prototype strain and immune-evasive variants, including Omicron and its sub-lineages. The immunogenicity of NVSI-06-09 as a booster vaccine was superior to that of BBIBP-CorV. (Funded by LIBP and BIBP of Sinopharm; ClinicalTrials.gov number, NCT05293548).
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.09.06.22279625v1?rss=1
Authors: Kannian, P., Mahanathi, P., Gracemary, A., Kumarasamy, N., Challacombe, S. J.
Abstract: Knowledge is limited on mucosal immunity induction and longitudinal responses to vaccination against SARS CoV2. Here, we determined serum and salivary antibodies and cytokines after three Covishield vaccine doses. Sera from 205 healthcare workers, HCWs one month after first dose; one, three and six months after second dose; paired sera and stimulated whole mouth fluid, SWMF from 10 HCWs one, three and six months after third dose were tested for anti spike SARS CoV2 antibodies by ECLIA and for cytokines by ELISA and cytokine bead arrays. One month after second dose, antibodies had increased significantly, 6 fold, in COVID naive group, but declined, 1.5 fold, in those previously exposed to COVID. At one month after first dose, IL10 levels were statistically higher in the previously COVID exposed group compared to COVID naive group, p less than 0.02. Breakthrough infections were 44 percent in COVID naive group, while re infections were 27 percent in COVID exposed group, p less than 0.02. Proinflammatory cytokines IL17, IL21 at one month after first and second doses, and memory cytokines IL7, IL15 at three and six months after second dose were minimal. Antibodies spiked at one month after third dose and declined by three and six months after third dose similar to post second dose. Paired sera and SWMF at one and six months after third dose lacked adaptive immunity cytokine expression. Innate immunity cytokines: MIG, MCP1, IL8, TNFa, IL6, IL1b showed a declining trend in serum, but were sustained in SWMF. Thus, our findings suggest that first dose acts as an antibody boost, while second dose induces antibody anergy in the previously COVID exposed group. Rapidly declining antibodies and minimal T cell cytokines raises concerns over their durability in subsequent virus exposures. Sustained innate cytokines emanating from the oral mucosa warrant further in depth explorations.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.09.06.22279606v1?rss=1
Authors: Dagan, R., van der Beek, B. A., Ben-Shimol, S., Greenberg, D., Shemer Avni, Y., Weinberger, D. M., Danino, D.
Abstract: BACKGROUND: In young children, rates of community-acquired alveolar pneumonia (CAAP) or invasive pneumococcal disease (IPD) have been associated with respiratory syncytial virus (RSV), human metapneumovirus (hMPV), influenza (flu), and parainfluenza (PIV) (collectively termed here as pneumococcal disease-associated viruses [PDA-viruses]). However, their contribution to the pathogenesis of pneumococcal-associated disease has not yet been elucidated. The COVID-19 pandemic provided a unique opportunity to examine the question. METHODS: This prospective study comprised all children less than 5 years, living in southern Israel, during 2016 through 2021. The data were derived from multiple ongoing prospective cohort surveillance programs and include: hospital visits for CAAP, non-CAAP lower respiratory infections (LRI); nasopharyngeal pneumococcal carriage ( less than 3 years of age); respiratory virus activity; all-ages COVID-19 episodes; and IPD in children less than 5 years (nationwide) A hierarchical negative binominal regression model was developed to estimate the proportion of the disease outcomes attributable to each of the viruses from monthly time series data, stratified by age and ethnicity. A separate model was fit for each outcome, with covariates that included a linear time trend, 12-month harmonic variables to capture unexplained seasonal variations, and the proportion of tests positive for each virus in that month. FINDINGS: During 2016 through 2021, 3,204, 26,695, 257, and 619 episodes of CAAP, non-CAAP LRI, pneumococcal bacteremic pneumonia and non-pneumonia IPD, respectively, were reported. Compared to 2016-2019, broad declines in the disease outcomes were observed shortly after the pandemic surge, coincident with a complete disappearance of all PDA-viruses and continued circulation of rhinovirus (RhV) and adenovirus (AdV). From April 2021, off-season and abrupt surges of all disease outcomes occurred, associated with similar dynamics among the PDA-viruses, which re-emerged sequentially. Using our model fit to the entire 2016-2021 period, 82% (95% CI, 75-88%) of CAAP episodes in 2021 were attributable to the common respiratory viruses, as were 22%-31% of the other disease outcomes. Virus-specific contributions to CAAP were: RSV, 49% (95% CI, 43-55%); hMPV, 13% (10-17%); PIV, 11% (7-15%); flu, 7% (1-13%). RhV and AdV did not contribute. RSV was the main contributor in all outcomes, especially in infants. Pneumococcal carriage prevalence remained largely stable throughout the study. INTERPRETATION: RSV and hMPV play a critical role in the burden of CAAP and pneumococcal disease in children. Interventions targeting these viruses could have a secondary effect on the disease burden typically attributed to bacteria.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.09.03.22279565v1?rss=1
Authors: Aiwara, S., Kevau, I. H., Linge, D., Aglua, I.
Abstract: Abstract Background Tuberculous meningitis is the most severe form of extrapulmonary TB and accounted for 5 % of 10 million TB cases globally in the WHO 2018 report, with mortality as high as 19.35% in children and 30% in adults. Clinicians in resource-poor settings are often challenged with limited diagnostic and therapeutic options for optimal patient care, and often rely on clinical parameters for diagnosis, treatment, monitoring and outcome prediction. Aim This study was done to identify potential clinical predictors of i) length of in-hospital stay, and ii) death or discharge at 28 days, amongst Melanesian adults with TB meningitis at the Kundiawa General Hospital in Simbu Province of Papua New Guinea. Method A retrospective observational study was conducted on 65 Melanesian adults with TB meningitis at the Kundiawa General Hospital in Simbu province between 2015 and 2019. Result High case fatality (48%) and mortality rates (2.22 per 100,000 per year) for TB Meningitis in this study. Even higher case fatality of 90.9% with HIV co-infection. Parameters associated with higher 28-day mortality included admission GCS (P=0.039, 95% CI), HIV-TBM co-infection (P=0.049, 95% CI), positive fluid balance 24 hours after admission (P=0.061, 95% CI) and male gender (P=0.057, 95% CI). Conclusion Study showed high case fatality (48%) and mortality rates (2.22 per 100,000 per year) for adult TB Meningitis, with even higher case fatality (90.9%) for HIV-TB co-infection. Admission GCS, positive fluid balance 24 hours after admission, HIV-TB co-infection and male gender were associated with higher 28-day mortality.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.09.02.22279519v1?rss=1
Authors: Mwakibete, L., Takahashi, S., Ahyong, V., Black, A., Rek, J., Ssewanyana, I., Kamya, M., Dorsey, G., Jagannathan, P., Rodriguez-Barraquer, I., Tato, C. M., Greenhouse, B.
Abstract: Background: Causes of non-malarial fevers in sub-Saharan Africa remain understudied. We hypothesized that metagenomic next-generation sequencing (mNGS), which allows for broad genomic-level detection of infectious agents in a biological sample, can systematically identify potential causes of non-malarial fevers. Methods and Findings: The 212 participants in this study were of all ages and were enrolled in a longitudinal malaria cohort in eastern Uganda. Between December 2020 and August 2021, respiratory swabs and plasma samples were collected at 313 study visits where participants presented with fever and were negative for malaria by microscopy. Samples were analyzed using CZ ID, a web-based platform for microbial detection in mNGS data. Overall, viral pathogens were detected at 123 of 313 visits (39%). SARS-CoV-2 was detected at 11 visits, from which full viral genomes were recovered from nine. Other prevalent viruses included Influenza A (14 visits), RSV (12 visits), and three of the four strains of seasonal coronaviruses (6 visits). Notably, 11 influenza cases occurred between May and July 2021, coinciding with when the Delta variant of SARS-CoV-2 was circulating in this population. The primary limitation of this study is that we were unable to estimate the contribution of bacterial microbes to non-malarial fevers, due to the difficulty of distinguishing bacterial microbes that were pathogenic from those that were commensal or contaminants. Conclusions: These results revealed the co-circulation of multiple viral pathogens likely associated with fever in the cohort during this time period. This study illustrates the utility of mNGS in elucidating the multiple causes of non-malarial febrile illness. A better understanding of the pathogen landscape in different settings and age groups could aid in informing diagnostics, case management, and public health surveillance systems.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.09.03.22279558v1?rss=1
Authors: Johnson, S. A., Phillips, E., Adele, S., Longet, S. A., Malone, T., Mason, C., Stafford, L., Jamsen, A., Gardiner, S., Deeks, A., Neo, J., Blurton, E. J., White, J., Ali, M., Kronsteiner-Dobramysl, B., Skelly, D., Jeffery, K. J., Conlon, C. P., Goulder, P., Carroll, M., Barnes, E., Klenerman, P., Dunachie, S., PITCH Consortium
Abstract: Background: T cells are important in preventing severe disease from SARS-CoV-2, but scalable and field-adaptable alternatives to expert T cell assays are needed. The interferon-gamma release assay QuantiFERON platform was developed to detect T cell responses to SARS-CoV-2 from whole blood with relatively basic equipment and flexibility of processing timelines. Methods: 48 participants with different infection and vaccination backgrounds were recruited. Whole blood samples were analysed using the QuantiFERON SARS-CoV-2 assay in parallel with the well-established Protective Immunity from T Cells in Healthcare workers (PITCH) ELISpot, which can evaluate spike-specific T cell responses. Aims: The primary aims of this cross-sectional observational cohort study were to establish if the QuantiFERON SARS-Co-V-2 assay could discern differences between specified groups and to assess the sensitivity of the assay compared to the PITCH ELISpot. Findings: The QuantiFERON SARS-CoV-2 distinguished acutely infected individuals (12-21 days post positive PCR) from naive individuals (p less than 0.0001) with 100% sensitivity and specificity for SARS-CoV-2 T cells, whilst the PITCH ELISpot had reduced sensitivity (62.5%) for the acute infection group. Sensitivity with QuantiFERON for previous infection was 12.5% (172-444 days post positive test) and was inferior to the PITCH ELISpot (75%). Although the QuantiFERON assay could discern differences between unvaccinated and vaccinated individuals (55-166 days since second vaccination), the latter also had reduced sensitivity (55.5%) compared to the PITCH ELISpot (66.6%). Conclusion: The QuantiFERON SARS-CoV-2 assay showed potential as a T cell evaluation tool soon after SARS-CoV-2 infection but has lower sensitivity for use in reliable evaluation of vaccination or more distant infection.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.09.02.22279419v1?rss=1
Authors: Olson, D., Lamb, M. M., Connery, A. K., Colbert, A. M., Calvimontes, M., Bauer Herbruger, D., Paniagua-Avila, M. A., Martinez, M. A., Arroyave, P., Hernandez, S., Colborn, K. L., Roell, Y., Waggoner, J. J., Natrajan, M. S., Anderson, E. J., Bolanos, G. A., El Sahly, H. M., Munoz, F. M., Asturias, E. J.
Abstract: Objective: We aimed to evaluate the association between cumulative illness with neurodevelopment and growth outcomes in a birth cohort of Guatemalan infants. Study Design: From June 2017 to July 2018, infants 0-3 months of age living in a resource-limited region of rural southwest Guatemala were enrolled and completed weekly at-home surveillance for caregiver-reported cough, fever and vomiting/diarrhea. They also underwent anthropometric assessments and neurodevelopmental testing with the Mullen Scales of Early Learning (MSEL) at enrollment, six months, and one year. Results: Out of 499 enrolled infants, 430 (86.2%) completed all study procedures and were included in the analysis. At 12-15 months of age, 140 (32.6%) infants had stunting (length-for-age Z [LAZ] score less than -2 SD) and 72 (16.7%) had microcephaly (occipital-frontal circumference [OFC] less than -2 SD of the mean). In multivariable analysis, greater cumulative weeks of reported cough illness (beta=-0.08/illness-week, p=0.06) and febrile illness (beta=-0.36/illness-week, p less than 0.001) were marginally or significantly associated with lower MSEL Early Learning Composite (ELC) Score at 12-15 months, respectively; there was no association with any illness (cough, fever, and/or vomiting/diarrhea; p=0.27) or with cumulative weeks of diarrheal/vomiting illness alone (p=0.66). No association was shown between cumulative weeks of illness and stunting or microcephaly at 12-15 months. Conclusions: These findings highlight the negative cumulative consequences of frequent febrile and respiratory illness on neurodevelopment during infancy. Future studies should explore the inflammatory profile associated with these syndromic illnesses and their impact on neurodevelopment in the first years of life.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.09.01.22279488v1?rss=1
Authors: Langford, B. J., Soucy, J.-P. R., Leung, V., So, M., Kwan, A. T., Portnoff, J. S., Bertagnolio, S., Raybardhan, S., MacFadden, D., Daneman, N.
Abstract: Background: COVID-19 and antimicrobial resistance (AMR) are two intersecting global public health crises. Objective: We aim to describe the impact of the COVID-19 pandemic on AMR across healthcare settings. Data Source: A search was conducted in December 2021 in World Health Organization COVID-19 Research Database with forward citation searching up to June 2022. Study Eligibility: Studies evaluating the impact of COVID-19 on AMR in any population were included and influencing factors were extracted. Methods: Pooling was done separately for Gram-negative and Gram-positive organisms. Random effects meta-analysis was performed. Results: Of 6036 studies screened, 28 were included and 23 provided sufficient data for meta-analysis. The majority of studies focused on hospital settings (n=25, 89%). The COVID-19 pandemic was not associated with a change in the incidence density (IRR 0.99, 95% CI: 0.67 to 1.47) or proportion (RR 0.91, 95% CI: 0.55 to 1.49) of MRSA or VRE cases. A non-statistically significant increase was noted for resistant Gram-negatives (i.e., ESBL, CRE, MDR or carbapenem-resistant Pseudomonas or Acinetobacter species, IRR 1.64, 95% CI: 0.92 to 2.92; RR 1.08, 95% CI: 0.91 to 1.29). The absence of enhanced IPAC and/or ASP initiatives was associated with an increase in Gram-negative AMR (RR 1.11, 95% CI: 1.03 to 1.20), while studies that did report implementation of these initiatives noted no change in Gram-negative AMR (RR 0.80, 95% CI: 0.38 to 1.70). However, a test for subgroup differences showed no statistically significant difference between these groups (P=0.40) Conclusion: The COVID-19 pandemic could play an important role in the emergence and transmission of AMR, particularly for Gram-negative organisms in hospital settings. There is considerable heterogeneity in both the AMR metrics utilized and the rate of resistance reported across studies. These findings reinforce the need for strengthened infection prevention, antimicrobial stewardship, and AMR surveillance in the context of the COVID-19 pandemic. PROSPERO registration: CRD42022325831
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.31.22279264v1?rss=1
Authors: Di Fusco, M., Sun, X., Moran, M. M., Coetzer, H., Zamparo, J. M., Puzniak, L., Alvarez, M. B., Tabak, Y. P., Cappelleri, J. C.
Abstract: BackgroundAlthough there is extensive literature on the clinical benefits of COVID-19 vaccination, data on humanistic effects are limited. This study evaluated the impact of SARS- CoV-2 infection on symptoms, Health Related Quality of Life (HRQoL) and Work Productivity and Impairment (WPAI) prior to and one month following infection, and compared results between individuals vaccinated with BNT162b2 and those unvaccinated.
MethodsSubjects with greater than or equal to 1 self-reported symptom and positive RT-PCR for SARS-CoV-2 at CVS Health US test sites were recruited between 01/31/2022-04/30/2022. Socio-demographics, clinical characteristics and vaccination status were evaluated. Self-reported symptoms, HRQoL, and WPAI outcomes were assessed using questionnaires and validated instruments (EQ-5D-5L, WPAI-GH) across acute COVID time points from pre-COVID to Week 4, and between vaccination groups. Mixed models for repeated measures were conducted for multivariable analyses, adjusting for several covariates. Effect size (ES) of Cohens d was calculated to quantify the magnitude of outcome changes within and between vaccination groups.
ResultsThe study population included 430 subjects: 197 unvaccinated and 233 vaccinated with BNT162b2. Mean (SD) age was 42.4 years (14.3), 76.0% were female, 38.8% reported prior infection and 24.2% at least one comorbidity. Statistically significant differences in outcomes were observed compared with baseline and between groups. The EQ-Visual analogue scale scores and Utility Index dropped in both cohorts at Day 3 and increased by Week 4, but did not return to pre-COVID levels. The mean changes were statistically lower in the BNT162b2 cohort at Day 3 and Week 4. The BNT162b2 cohort reported lower prevalence and fewer symptoms at index date and Week 4. At Week 1, COVID-19 had a large impact on all WPAI-GH domains: the work productivity time loss among unvaccinated and vaccinated was 65.0% and 53.8%, and the mean activity impairment was 50.2% and 43.9%, respectively. With the exception of absenteeism at Week 4, the BNT162b2 cohort was associated with statistically significant less worsening in all WPAI-GH scores at both Week 1 and 4.
ConclusionsCOVID-19 negatively impacted HRQoL and work productivity among mildly symptomatic outpatients. Compared with unvaccinated, those vaccinated with BNT162b2 were less impacted by COVID-19 infection and recovered faster.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.30.22279403v1?rss=1
Authors: Shrestha, N. K., Shu, J., Shrestha, N. K., Gordon, S. M.
Abstract: Among 1282 patients with a positive Clostridioides difficile PCR test who were retested within 14 days, the proportion of positive tests rapidly decreased on successive days within the first week since initiation of treatment. Between days 7 and 14 after treatment initiation, approximately 25% of tests remained positive.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.31.22279414v1?rss=1
Authors: Zaeck, L. M., Lamers, M. M., Verstrepen, B. E., Bestebroer, T. M., van Royen, M. E., Gotz, H., Shamier, M. C., van Leeuwen, L. P. M., Schmitz, K. S., Alblas, K., van Efferen, S., Bogers, S., Scherbeijn, S., Rimmelzwaan, G. F., van Gorp, E. C. M., Koopmans, M. P. G., Haagmans, B. L., GeurtsvanKessel, C. H., de Vries, R. D.
Abstract: In July 2022, the ongoing monkeypox (MPX) outbreak was declared a public health emergency of international concern by the World Health Organization. Modified vaccinia virus Ankara (MVA-BN, also known as Imvamune, Jynneos, or Imvanex) is a 3rd generation smallpox vaccine that was generated by serial passaging of the more pathogenic parental vaccinia virus (VACV), and is authorized as a vaccine against MPX in humans in a two-shot regimen. Up to now, there is a lack of data that demonstrate MPX virus (MPXV)-neutralizing antibodies in vaccinated individuals and vaccine efficacy data against MPXV infection. Here, we measure MVA-, VACV-, and MPXV-reactive binding and neutralizing antibodies with validated in-house assays in cohorts of historically smallpox-vaccinated, MPXV PCR-positive, and recently MVA-BN-vaccinated individuals. We show that MPXV neutralizing antibodies were detected across all cohorts in individuals with MPXV exposure as well as those who received historic (VACV) vaccination. However, a primary MVA-BN immunization series in non-primed individuals yields relatively low levels of MPXV neutralizing antibodies. As the role of MPXV neutralizing antibodies for protection against disease and transmissibility is currently unclear and no correlate of protection against MPXV infection has been identified yet, this raises the question how well vaccinated individuals are protected. Dose-sparing leads to lower antibody levels, whereas a third MVA vaccination further boosts the antibody response. Cohort studies following vaccinated individuals are necessary to further assess vaccine efficacy in risk populations and determine correlates of protection for this emerging pathogen.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.30.22278604v1?rss=1
Authors: Papazyan, R., Ferdyan, N., Srinivasan, K., Gonzalez, C., Shannon, B., Blount, K., Fuchs, B. C.
Abstract: Intestinal microbiome disruption is associated with recurrent Clostridioides difficile infection (rCDI), which poses a high risk of morbidity and mortality. Microbiome-based therapeutics are increasingly evaluated as a strategy to reduce rCDI, and their proposed mechanisms include restoration of the microbiota and microbiota-mediated functions, including bile acid (BA) metabolism. This study reports the development of a highly quantitative and sensitive assay for targeted metabolomic assessment of bile acids, and the application of the assay to profile bile acid composition in a Phase 2 trial of the investigational microbiota-based live biotherapeutic RBX2660 for reduction of rCDI (PUNCH CD2; NCT02299570). Participants were asked to provide stool samples before and up to 24 months after treatment. A liquid chromatography tandem mass spectrometry method was developed to extract and quantify 35 BAs from a total of 113 participant stool samples from 27 rCDI participants treated with RBX2660 in the double-blinded, placebo-controlled clinical trial. The results demonstrate a high-confidence assay as represented by sensitivity, linearity, accuracy, and precision of the output measurements of BAs. When the assay was utilized to assess stool samples from the clinical trial participants, primary BAs were the dominant BA species at baseline, consistent with the expected loss of commensals after broad-spectrum antibiotic treatment. As early as 7 days after RBX2660 administration, there was a significant drop in primary BAs concurrent with increased secondary BAs, and this profile was sustained through 24 months after RBX2660 administration. Taken together, we describe a robust assay that demonstrates altered BA metabolism associated with RBX2660 administration, shifting towards a profile that is consistent with a healthier BA profile and clinical response.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.30.22279402v1?rss=1
Authors: Tashi, T., Upadhye, A., Kundu, P., Wu, C., Menant, S., Soares, R. R., Ferreira, M. U., Longley, R. J., Mueller, I., Hoang, Q. Q., Tham, W.-H., Rayner, J. C., Scopel, K. K., Junior, J. C. L., Tran, T. M.
Abstract: BackgroundTo make progress towards malaria elimination, a highly effective vaccine targeting Plasmodium vivax is urgently needed. Evaluating the kinetics of natural antibody responses to vaccine candidate antigens after acute vivax malaria can inform the design of serological markers of exposure and vaccines.
Methodology/Principal FindingsThe responses of IgG antibodies to 9 P. vivax vaccine candidate antigens were evaluated in longitudinal serum samples from Brazilian individuals collected at the time of acute vivax malaria and 30, 60, and 180 days afterwards. Antigen-specific IgG correlations, seroprevalence, and half-lives were determined for each antigen using the longitudinal data. Antibody reactivity against Pv41 and PVX_081550 strongly correlated within each of the four time points. The analysis identified robust responses in terms of magnitude and seroprevalence against Pv41 and PvGAMA at 30 and 60 days. Among the 8 P. vivax antigens demonstrating >50% seropositivity across all individuals, antibodies specific to PVX_081550 had the longest half-life 100 days (95% CI, 83--130 days), followed by PvRBP2b (91 days; 95% CI, 76--110 days) and Pv12 (82 days; 95% CI, 64--110 days).
Conclusion/SignificanceThis study provides an in-depth assessment of the kinetics of antibody responses to key vaccine candidate antigens in Brazilians with acute vivax malaria. Follow-up studies are needed to determine whether the longer-lived antibody responses induced by natural infection are effective in controlling blood-stage infection and mediating clinical protection.
AUTHOR SUMMARYTo successfully eliminate malaria, highly effective vaccines against the two major human malaria species, Plasmodium falciparum and Plasmodium vivax, will be needed. Vaccines against the blood form of malaria generate antibodies that target specific proteins on the Plasmodium parasite to reduce its replication within the host. Studying the antibody response after natural malaria infection can help identify blood markers of parasite exposure and also shed light on the magnitude and longevity of antibodies to vaccine candidate proteins. We performed a study to determine the frequency, magnitude, and longevity of natural antibody responses against nine P. vivax vaccine candidate proteins in patients with vivax malaria in Brazil. These proteins were selected based on prior studies demonstrating that antibodies against these proteins were either associated with protection against vivax malaria or have been tested as blood markers of recent infection with vivax malaria. We identify specific vivax proteins that produce more frequent and longer-lived antibody responses in this population.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.30.22279397v1?rss=1
Authors: Stoddard, M., Yuan, L., Sarkar, S., Mangalaganesh, S., Nolan, R. P., Bottino, D., Hather, G., Hochberg, N. S., White, L. F., Chakravarty, A.
Abstract: The ongoing COVID-19 pandemic has placed an unprecedented burden on global health. Crucial for managing this burden, the existing SARS-CoV-2 vaccines have substantially reduced the risk of severe disease and death up to this point. The induction of neutralizing antibodies (nAbs) by these vaccines leads to protection against both infection and severe disease. However, pharmacokinetic (PK) waning and rapid viral evolution degrade neutralizing antibody binding titers, leading to a rapid loss of vaccinal protection against infection occurring on the order of months after vaccination. Additionally, inter-individual heterogeneity in the strength and durability of the vaccine-induced neutralizing response to SARS-CoV-2 can create a further public-health risk by placing a subset of the population at risk. Here we incorporate the heterogeneity in inter-individual response into a pharmacokinetic/ pharmacodynamic (PK/PD) model to project the degree of heterogeneity in immune protection. We extend our model-based approach to examine the impact of evolutionary immune evasion on vaccinal protection. Our findings suggest that viral evolution can be expected to impact the effectiveness of vaccinal protection against severe disease, particularly for individuals with a shorter duration of immune response. One possible solution to immune heterogeneity may be more frequent boosting for individuals with a weaker immune response. We demonstrate a model-based approach to targeted boosting that involves the use of the ECLIA RBD assay to identify individuals whose immune response is insufficient for protection against severe disease. Our work suggests that vaccinal protection against severe disease is not assured and provides a path forward to reducing the risk to immunologically vulnerable individuals.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.30.22279408v1?rss=1
Authors: Alhamid, G., Tombuloglu, H., Motabagani, D., Motabagani, D., Rabaan, A. A., Unver, K., Dorado, G., Al-Suhaimi, E., Unver, T.
Abstract: The coronavirus disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has caused millions of infections and deaths worldwide, since it infected humans almost three years ago. Improvements of current assays and development of new rapid tests or to diagnose SARS-CoV-2 are urgent. Reverse-transcription loop-mediated isothermal amplification (RT-LAMP) is a rapid and propitious assay, allowing to detect both colorimetric and/or fluorometric nucleic-acid amplifications. This study describes the analytical and clinical evaluation of RT-LAMP assay for detection of SARS-CoV-2, by designing LAMP primers targeting N (nucleocapsid phosphoprotein), RdRp (polyprotein), S (surface glycoprotein) and E (envelope protein) genes. The assays performance was compared with the gold-standard RT-PCR, yielding 94.6% sensitivity and 92.9% specificity. Among the tested primer sets, the ones for S and N genes had the highest analytical sensitivity, showing results in about 20 minutes. The colorimetric and fluorometric comparisons revealed that the latter is faster than the former. The limit of detection (LoD) of RT-LAMP reaction in both assays is 50 copies/{micro}l of reaction mixture. However, the simple eye-observation advantage of the colorimetric assay (with a color change from yellow to red) serves a promising on-site point-of-care testing method anywhere, including, for instance, laboratory and in-house applications.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.31.22279450v1?rss=1
Authors: Parag, K. V., Obolski, U.
Abstract: The effective reproduction number R is a prominent statistic for inferring the transmissibility of infectious diseases and the effectiveness of interventions. R purportedly provides an easy-to-interpret threshold for deducing if an epidemic will grow (R >1) or decline (R < 1). We posit that this interpretation can be misleading and overconfident when applied to infections aggregated from groups with heterogeneous dynamics. In these settings, R implicitly weights the dynamics of groups by their number of circulating infections. This induces losses in sensitivity to the dynamics of high-risk groups that may spur resurgences, promotes premature indications of epidemic control, and renders the R = 1 threshold uninformative. Applying E-optimal experimental design theory, we derive the risk averse reproduction number E to ameliorate these issues. Using analytic approaches, simulations, and a real-world case study, we find that E achieves more meaningful consensus of the dynamics across groups without being overconfident in its estimates. An E >1 generates timely resurgence signals (upweighting the impact of high-risk groups), while E < 1 ensures constituent sub-outbreaks are under control. We propose E as an alternative to R for informing policy and assessing transmissibility over large scales (e.g., state or nationwide), where well-mixed assumptions break down.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.09.01.22279485v1?rss=1
Authors: Maxwell, L., Shreedhar, P., Levis, B., Chavan, S. A., Akter, S., Carabali, M.
Abstract: BackgroundIndividual participant data meta-analyses (IPD-MAs), which include harmonising and analysing participant-level data from related studies, provide several advantages over aggregate data meta-analyses, which pool study-level findings. IPD-MAs are especially important for building and evaluating diagnostic and prognostic models, making them an important tool for informing the research and public health responses to COVID-19.
MethodsWe conducted a rapid systematic review of protocols and publications from planned, ongoing, or completed COVID-19-related IPD-MAs to identify areas of overlap and maximise data request and harmonisation efforts. We searched four databases using a combination of text and MeSH terms. Two independent reviewers determined eligibility at the title-abstract and full-text stage. Data were extracted by one reviewer into a pretested data extraction form and subsequently reviewed by a second reviewer. Data were analysed using a narrative synthesis approach. A formal risk of bias assessment was not conducted.
ResultsWe identified 31 COVID-19-related IPD-MAs, including five living IPD-MAs and ten IPD-MAs that limited their inference to published data (e.g., case reports). We found overlap in study designs, populations, exposures, and outcomes of interest. For example, 26 IPD-MAs included RCTs; 17 IPD-MAs were limited to hospitalised patients. Sixteen IPD-MAs focused on evaluating medical treatments, including six IPD-MAs for antivirals, four on antibodies, and two that evaluated convalescent plasma.
ConclusionsCollaboration across related IPD-MAs can leverage limited resources and expertise by expediting the creation of cross-study participant-level data datasets, which can, in turn, fast-track evidence synthesis for the improved diagnosis and treatment of COVID-19.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.30.22279344v1?rss=1
Authors: Buckner, C., Kardava, L., El Merhebi, O., Narpala, S., Serebryannyy, L., Lin, B., Wang, W., Zhang, X., Lopes de Assis, F., Kelly, S., Teng, I.-T., McCormack, G., Praiss, L., Seamon, C., Rai, M. A., Kalish, H., Kwong, P., Proschan, M., McDermott, A., Fauci, A., Chun, T.-W., Moir, S.
Abstract: SARS-CoV-2 mRNA booster vaccines provide protection from severe disease, eliciting strong immunity that is further boosted by previous infection. However, it is unclear whether these immune responses are affected by the interval between infection and vaccination. Over a two-month period, we evaluated antibody and B-cell responses to a third dose mRNA vaccine in 66 individuals with different infection histories. Uninfected and post-boost but not previously infected individuals mounted robust ancestral and variant spike-binding and neutralizing antibodies, and memory B cells. Spike-specific B-cell responses from recent infection were elevated at pre-boost but comparatively less so at 60 days post-boost compared to uninfected individuals, and these differences were linked to baseline frequencies of CD27lo B cells. Day 60 to baseline ratio of BCR signaling measured by phosphorylation of Syk was inversely correlated to days between infection and vaccination. Thus, B-cell responses to booster vaccines are impeded by recent infection.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.29.22279247v1?rss=1
Authors: Feray, C., Allain, V., Allain, J.-L., roche, B., Desterke, C., Kounis, I., Demir, z., Roque-Afonso, A.-M., Coilly, A., Samuel, D., Caillat-Zucman, S.
Abstract: BackgroundOrgan transplant recipients are at high risk of viral infections but show lower humoral vaccine responsiveness than immunocompetent individuals. HLA evolutionary divergence (HED) quantifies the sequence differences between homologous HLA alleles and reflects the breadth of the immunopeptidome presented to T lymphocytes.
MethodsWe retrospectively investigated the impact of HED on humoral response to SARS-CoV-2 mRNA vaccine in 310 liver transplant recipients (undetectable anti-spike IgG titers considered as no response, less than or equal to 250 BAU/mL as moderate response, greater than 250 BAU/mL as strong response) and to Hepatitis B virus (HBV) vaccine in 424 liver transplant candidates (anti-HBs IgG less than 10 mIU/mL considered as no response, 10-100 mIU/mL as moderate reponse, greater than or equal to 100 mIU/mL as strong response). HED between aligned allele pairs at HLA-A, -B, -DRB1 and- DQB1 loci were measured as a continuous metric using the Grantham distance. The impact of HED on vaccine responses was analyzed through ordinal logistic regression and inverse probability weighting approach based on generalised propensity scores.
FindingsFor both vaccines, HED at the DQB1 locus, but not at other loci, was significantly higher in responders than in others, independent of covariates associated to the response (age, time since transplant, hemoglobin levels, combined graft, immunosuppression with steroids or mycophenolate for SARS-CoV-2 vaccine; age, gender, and liver disease for HBV vaccine).
InterpretationDQB1 HED is a critical determinant of humoral response to vaccines in liver transplant recipients. This metric could guide the design of future vaccines as it predicts the magnitude of the repertoire of vaccine-derived peptides presented to CD4 helper T cells.
FundingInstitut National de la Sante et de la Recherche Medicale (INSERM)
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.29.22279317v1?rss=1
Authors: Lien, C. E., Liu, M.-C., Wang, N.-C., Liu, L. T. -C., Wu, C.-C., Tang, W.-H., Lian, W.-C., Huang, K.-Y. A., Chen, C.
Abstract: BackgroundThe use of variant-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine as a booster is being evaluated to overcome reduced neutralisation of variants induced by the original SARS-CoV-2 vaccine and waning protection over time.
MethodsThis is a phase one, prospective, randomized, and open-labeled trial to study the safety and immunogenicity of a booster dose consisting of a subunit vaccine based on the stabilized prefusion SARS-CoV-2 spike protein, MVC-COV1901 or its Beta version, MVC-COV1901-Beta. One-hundred and seven participants aged greater than or equal to 18 and less than 55 years, who received two or three prior doses of MVC-COV1901 vaccines, were enrolled and were to receive a booster dose of either 15 mcg of MVC-COV1901, 15 mcg or 25 mcg of MVC-COV1901-Beta in 1:1:1 ratio. The primary endpoints were the incidences of adverse events and immunogenicity of the booster dose from Visit 2 (the day of the booster) to Visit 5 (four weeks after the booster). Cellular immunity was also investigated with memory B cell (MBC) and T cell assays.
FindingsAdverse reactions after either MVC-COV1901 or MVC-COV1901-Beta booster doses after two or three doses of MVC-COV1901 were comparable and mostly mild and transient. At four weeks after the booster dose, participants with two prior doses of MVC-COV1901 exhibited numerically higher levels of neutralising antibodies against SARS-CoV-2 or Beta variant than participants with three prior doses of MVC-COV1901 regardless of the type of booster used. However, compared to 15 mcg of MVC-COV1901, 25 mcg of MVC-COV1901-Beta significantly improved neutralising antibody titre against Beta variant and BA.4/BA.5 Omicron variant pseudoviruses. The booster dose also significantly increased the proportion of spike-specific MBCs, including those of Beta and Omicron variants.
InterpretationMVC-COV1901-Beta can be effectively used as a booster dose against SARS-CoV-2, including the circulating BA.4/BA.5 Omicron variant.
FundingMedigen Vaccine Biologics Corporation
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.27.22279297v1?rss=1
Authors: Blair, P. W., Mehta, R., Oppong, C., Som, T., Ko, E., Tsalik, E., Chenoweth, J., Rozo, M., Adams, N., Beckett, C., Woods, C., Salvador, M., Striegel, D., Brandsma, J., McKean, L., Mahle, R., William, H., Krishnan, S., Prouty, M., Letizia, A., Fox, A. T., Faix, D., Lawler, J. V., Duplessis, C., Gregory, M., Vantha, T., Owusu-Ofori, A., Onsong, D., Oduro, G., Schully, K. L., Clark, D. V.
Abstract: BackgroundDirect comparisons of sepsis screening tools for prognostication have largely been limited to single-centre or high-income countries despite a disproportionately high burden of sepsis in low- and middle-income countries (LMICs). We evaluated the performance of commonly used sepsis screening tools across prospective sepsis cohorts in the United States, Cambodia, and Ghana.
MethodsFrom 2014 to 2021, participants with 2 or more SIRS (Systemic Inflammatory Response Syndrome) criteria and suspected infection were enrolled in emergency departments and medical wards at hospitals in the Cambodia and Ghana and hospitalized participants with suspected infection were enrolled in the United States. Cox proportional hazards regression was performed, and Harrells C-statistic calculated to determine 28-day mortality prediction performance of the qSOFA score greater than or equal to 2, SIRS score greater than or equal to 3, NEWS greater than or equal to 5, MEWS greater than or equal to 5, or UVA score greater than or equal to 2, Screening tools were compared to baseline risk (age and sex) with the Wald test.
ResultsThe cohorts included 567 participants (42.9% female) including 187 participants from Kumasi, Ghana, 200 participants from Takeo, Cambodia, and 180 participants from Durham, North Carolina in the United States. The pooled mortality was 16.4% at 28-days. The mortality prediction accuracy increased from baseline risk with the MEWS (C-statistic: 0.63, 95% CI: 0.58, 0.68; p=0.002), NEWS (C-statistic: 0.68; 95% confidence interval [CI]: 0.64, 0.73; p less than 0.001), qSOFA (C-statistic: 0.70, 95% CI: 0.64, 0.75; p less than 0.001), UVA score (C-statistic: 0.73, 95% CI: 0.69, 0.78; p less than 0.001), but not with SIRS (0.60; 95% CI: 0.54, 0.65; p=0.13). Within individual cohorts, only the UVA score in Ghana performed better than baseline risk (C-statistic: 0.77; 95% CI: 0.71, 0.83; p less than 0.001).
ConclusionsAmong the cohorts, MEWS, NEWS, qSOFA, and UVA scores performed better than baseline risk, largely driven by accuracy improvements in Ghana, while SIRS scores did not improve prognostication accuracy. Prognostication scores should be validated within the target population prior to clinical use.
Key questionsWhat is already known on this topic - While single-centre cohorts and retrospective analyses have been performed, the optimal sepsis screening tool for prognostication in low- and middle-income countries is unknown.
What this study adds - The MEWS, NEWS, qSOFA scores, but not SIRS, were additive over baseline risk for prognostication in prospective hospitalized infection cohorts, but with variable additive performance within each cohort.
How this study might affect research, practice or policy - Prognostication scores should be validated within the target population prior to clinical use.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.29.22279355v1?rss=1
Authors: Chan, L. E., Casiraghi, E., Laraway, B. J., Coleman, B., Blau, H., Zaman, A., Harris, N. L., Wilkins, K., Valentini, G., Sahner, D., Haendel, M. A., Robinson, P. N., Bramante, C. T., Reese, J. T.
Abstract: BackgroundWith the continuing COVID-19 pandemic, identifying medications that improve COVID-19 outcomes is crucial. Studies suggest that use of metformin, an oral antihyperglycemic, is associated with reduced COVID-19 severity in individuals with diabetes compared to other antihyperglycemic medications. Some patients without diabetes, including those with polycystic ovary syndrome (PCOS) and prediabetes, are prescribed metformin for off-label use, which provides an opportunity to further investigate the effect of metformin on COVID-19.
ParticipantsIn this observational, retrospective analysis, we leveraged the harmonized electronic health record data from 53 hospitals to construct cohorts of COVID-19 positive, metformin users without diabetes and propensity-weighted control users of levothyroxine (a medication for hypothyroidism that is not known to affect COVID-19 outcome) who had either PCOS (n = 282) or prediabetes (n = 3136). The primary outcome of interest was COVID-19 severity, which was classified as: mild, mild ED (emergency department), moderate, severe, or mortality/hospice.
ResultsIn the prediabetes cohort, metformin use was associated with a lower rate of COVID-19 with severity of mild ED or worse (OR: 0.630, 95% CI 0.450 - 0.882, p < 0.05) and a lower rate of COVID-19 with severity of moderate or worse (OR: 0.490, 95% CI 0.336 - 0.715, p < 0.001). In patients with PCOS, we found no significant association between metformin use and COVID-19 severity, although the number of patients was relatively small.
ConclusionsMetformin was associated with less severe COVID-19 in patients with prediabetes, as seen in previous studies of patients with diabetes. This is an important finding, since prediabetes affects between 19 and 38% of the US population, and COVID-19 is an ongoing public health emergency. Further observational and prospective studies will clarify the relationship between metformin and COVID-19 severity in patients with prediabetes, and whether metformin usage may reduce COVID-19 severity.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.26.22279232v1?rss=1
Authors: Wang, C. Y., Peng, W.-J., Kuo, B.-S., Liu, H., Ho, Y.-H., Wang, M.-S., Yang, Y.-T., Chang, P.-Y., Shen, Y.-H., Hwang, K.-P.
Abstract: The SARS-CoV-2 non-Spike (S) structural protein targets of nucleocapsid (N), membrane (M) and envelope (E), critical in the host cell interferon response and memory T-cell immunity, have been grossly overlooked since the inception of COVID vaccine development. To pursue a universal (pan-sarbecovirus) vaccine against ever-emergent future mutants, we explored booster immunogenicity of UB-612, a multitope-vaccine that contains S1-RBD-sFc protein and sequence-conserved rationally designed promiscuous Th and CTL epitope peptides on the Sarbecovirus N, M and S2 proteins. To a subpopulation of infection-free participants (aged 18-85 years) involved in a two-dose Phase-2 trial, a UB-612 booster (third dose) was administered 6-8 months after the second dose. The immunogenicity was evaluated at 14 days post-booster with overall safety monitored until the end of study. The booster induced high viral-neutralizing antibodies against live Wuhan WT (VNT50, 1,711) and Delta (VNT50, 1,282); and against pseudovirus WT (pVNT50, 11,167) vs. Omicron BA.1/BA.2/BA.5 variants (pVNT50, 2,314/1,890/854), respectively. The lower primary neutralizing antibodies in the elderly were uplifted upon boosting to approximately the same high level in young adults. UB-612 also induced potent, durable Th1-oriented (IFN-{gamma}+-) responses (peak/pre-boost/post-boost SFU/106 PBMCs, 374/261/444) along with robust presence of cytotoxic CD8+ T cells (peak/pre-boost/post-boost CD107a+-Granzyme B+, 3.6%/1.8%/1.8%). Booster vaccination is safe and well tolerated without SAEs. By recognition against epitopes on Spike (S1-RBD and S2) and non-Spike (N and M) structure proteins, UB-612 provides potent, broad and long-lasting B-cell and T-cell memory immunity and offers a potential as a universal vaccine to fend off Omicrons and new VoCs.
SIGNIFICANCE STATEMENTThe Omicron has swept the globe with a rapid succession of dominating sublineages from BA.1, BA.2, to the current BA.5 with increasing infectivity and antibody evasion. Concerningly, the non-Spike structure proteins that promote T-cell immunity are grossly overlooked in vaccine development. Looking beyond short-interval booster jabs and omicron-updated vaccines, a pragmatic approach to curbing ever-emergent new mutants would be "universal (pan-Sarbecovirus) vaccines" targeting conserved nonmutable epitopes on coronavirus. UB-612, a multitope-vaccine armed with Spike (S1-RBD and S2) and non-Spike targets (Nucleocapsid N and Membrane M), allows booster vaccination to elicit potent, broadly-recognizing, durable B- and T-cell memory immunity. Sequence-conserved epitope peptides were rationally-designed from S2, N and M proteins to synergistically enhance memory helper and cytotoxic T-cell immunity and B-cell immunity.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.29.22279332v1?rss=1
Authors: Andolina, C., Ramjith, J., Rek, J., Lanke, K., Okoth, J., Grignard, L., Arinaitwe, E., Briggs, J. J., Bailey, J., Aydemir, O., Kamya, M. R., Greenhouse, B., Dorsey, G., Staedke, S. G., Drakeley, C., Jonker, M., Bousema, T.
Abstract: Malaria transmission depends on the presence of Plasmodium gametocytes that are the only parasite life stage that can infect mosquitoes. Gametocyte production varies between infections and over the course of infections. Infection duration is influenced by host and parasite characteristics, and is highly important for gametocyte production but poorly quantified. Between 2017-2019 an all-age cohort from Tororo, eastern Uganda was followed by continuous passive and routine assessments. Among 104 longitudinally monitored incident infections coming from 98 individuals, we observed that nearly all infections lasting 3 or more months initiated gametocyte production prior to clearance. However, the majority of infections were of shorter duration (<28 days) and were cleared before gametocytes were detectable. Infections in individuals with sickle-cell trait were more likely to produce gametocytes and produced gametocytes at higher densities. Our findings suggest that a large proportion of infections may be too short in duration and of too low density to contribute to onward transmission.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.29.22279270v1?rss=1
Authors: Mego, L. G., Zethu, N. Z., Kebede, N.
Abstract: BackgroundIn Ethiopia, Cutaneous Leishmaniasis (CL) is a common infectious disease. However, existing knowledge on community awareness is scarce.
ObjectiveObjectives is to access knowledge, attitude, and practices about CL in Sodo District.
MethodsPrimary quantitative method using a cross-sectional descriptive approach was applied. Data were collected from face-to-face interviews held with 423 households between January to April 2018. Knowledge, attitude, and practice scores were obtained by aggregating responses to questions. Levels of these outcomes were determined by dichotomizing the generated scores using their mean vales. Percentages, frequency and mean values were used to descriptively understand the data. Logistic regression was used to model the binary outcomes. R Package Version 3.02 was used to conduct the statistical analysis.
ResultsOf 423 participants 263 (61.9%), 226 (53.4%), and 213 (50.4%) have satisfactory knowledge, favourable attitude, and good practice about leishmaniasis. Majority are unable to identify leishmaniasis and unaware of its cause and transmission. Sandfly is considered "important biting and blood-sucking insect" by 210 (49.6%) but knowledge on biting time and breeding place was unsatisfactory. Most believed CL can be treated, is a serious problem and have a disfiguring outcome. However, most (59.3%, n=251) prefer use of traditional medication. Concerning practice, 288 (68.1%) have bed nets but personal protective measures are rarely used.
ConclusionThe level of overall knowledge and attitudes and practice in the current study was not adequate. This finding implies that there is a need for intensified education regarding CL.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.26.22279009v1?rss=1
Authors: Schurz, H., Naranbhai, V., Yates, T., Gilchrist, J., Parks, T., Dodd, P., Möller, M., Hoal, E. G., Morris, A., Hill, A. V. S., van Crevel, R., Vanlaarhoven, A., Ottenhoff, T., Metspalu, A., Mägi, R., Meyer, C., Ellis, M., Thye, T., Mahasirimongkol, S., Pasomsub, E., Tokunaga, K., Omae, Y., Yanai, H., Mushiroda, T., Kubo, M., Takahashi, A., Kamatani, Y., Alisjahbana, B., Liu, W., Sheng, A.-d., Yang, Y.
Abstract: The heritability of susceptibility to tuberculosis disease (TB) has been well recognized. Over one-hundred genes have been studied as candidates for TB susceptibility, and several variants were identified by genome-wide association studies (GWAS), but few replicate. We established the International Tuberculosis Host Genetics Consortium (ITHGC) to perform a multi-ancestry meta-analysis of GWAS including 14153 cases and 19536 controls of African, Asian, and European ancestry. Our analyses demonstrate a substantial degree of heritability (pooled polygenic h2=26.3% 95% CI 23.7-29.0%) for susceptibility to TB that is shared across ancestries, highlighting an important host genetic influence on disease. We identified one global host genetic correlate for TB at genome-wide significance (p<5x10-8) in the human leukocyte antigen (HLA)-II region (rs28383206, p-value = 5.2x10-9). These data demonstrate the complex shared genetic architecture of susceptibility to TB and the importance of large scale GWAS analysis across multiple ancestries experiencing different levels of infection pressures.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.30.22279374v1?rss=1
Authors: Sossen, B., Richards, A., Heinsohn, T., Frascella, B., Balzarini, F., Oradini--Alacreu, A., Odone, A., Rogozinska, E., Hacker, B., Cobelens, F., Kranzer, K., Houben, R. M. G. J., Esmail, H.
Abstract: BACKGROUNDKey stages in TB disease can be delineated by radiology, microbiology and symptoms, but transition between relevant stages remains unclear. We sought to quantify progression and regression across the spectrum of TB disease by systematically reviewing studies of individuals with untreated TB undergoing follow up.
METHODSWe searched PubMED, EMBASE and Web of Science until December 31st 1960, the Index Medicus between 1895 and 1945, and extensive investigator collections without date restriction - in English and German. Eligible studies were observational cohorts and clinical trials, presenting adults/adolescents with TB or recent TB exposure, undergoing follow-up for at least 12 months without therapeutic intervention. Two authors independently reviewed titles/abstracts and full texts for inclusion. Quality was assessed with a modified Newcastle-Ottawa Score, excluding highly biased studies. Summary estimates were extracted to align with TB disease transitions in a conceptual model, and we used meta-analysis of proportions with random-effects to synthesise the extracted data. This study is registered with PROSPERO (CRD42019152585).
FINDINGS10477 titles were screened and 1648 full texts reviewed. 223 met inclusion criteria. 109 were excluded for high risk of bias and 90 did not have extractable data. 24 studies (34 cohorts) were included. Progression from microbiologically negative to positive disease in those with radiographic TB evidence occurred at an annualized rate of 9.71% (95% CI:6.17-13.34) with "active" TB imaging, and 1.06% (95% CI:0.31-1.82) with "inactive" TB imaging. Reversion from microbiologically-positive to -undetectable in prospective cohorts occurred at an annualized rate of 12.40% (95% CI: 6.81-17.99). Studies reported symptoms poorly not allowing for direct estimation of transitions for subclinical (asymptomatic, culture positive) disease.
INTERPRETATIONWe present the risk of progression in those with radiographic evidence of disease and the rate of self-cure for microbiologically positive disease to inform global disease burden estimates, clinical guidelines and policy decisions.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.25.22279201v1?rss=1
Authors: Sarwal, R., Dhamija, R. K., JAIN, K., Basavaraddi, I. V.
Abstract: BackgroundThe COVID-19 pandemic has brought unparalleled challenges for health systems worldwide, the impact of which has also been borne by the Healthcare Professionals (HCPs). Numerous studies have revealed the positive effects of Pranayama and Meditation on mental health. The effect of Pranayama in improving mental health of frontline HCP exposed to Covid-19 patients has not been studied.
Aim & ObjectiveThis quasi-randomized clinical trial was done to study the effect of especially designed Pranayama protocol on perceived stress, wellbeing and quality of life of frontline health care professionals who were exposed to COVID-19 patients in hospital settings.
MethodologyThis study was done with 280 frontline healthcare professionals (HCP) assigned duties with COVID-19 patients during September-November, 2020 in 5 government hospitals and COVID-19 quarantine/isolation centres in New Delhi, India. The HCPs were first assessed for COVID-19 infection in the past using antibody test, and only those found negative were recruited. The enrolled respondents were randomly assigned to two arms - an intervention arm where there were to practice 28-day Pranayama module (morning and evening sessions) under supervision of a trainer, and a Control arm where the HCPs continued routine physical activity (walking, jogging etc.). Baseline and end-line (total: 250 HCPs) Psychological parameters of Perceived Stress, Well Being and Quality of Life were collected through self-reported questionnaires.
ResultsThe intervention (HCPs: 123) and control (HCPs: 127) groups (Total: 250) were comparable in their demographic profile and baseline characteristics. Intervention with Pranayama module led to a significant reduction (Mean diff: -2.46; P-value: 0.028) in perceived stress score in the intervention group compared to the control group. The wellbeing index in Interventional group intervention showed a non-significant increase. The WHO Quality-of-life score increased in the intervention group as compared to the controls (mean difference 2.78, p-value: 0.17). Of its four components, the one for Psychological domain increased significantly (mean diff: 1.52, P-value: 0.019), while those for Physical domain and Environmental domains increased (mean diff: 0.64, P-value: 0.29 and mean diff: 0.68, p-value: 0.48) though not statistical significantly.
CconclusionThe intervention of twice daily practice of the Pranayama module for 28 days in frontline HCPs performing COVID-19 duties had a noteworthy effect in lowering Perceived Stress, improving perceived Quality of life, especially its Psychological domains as measured through standardized questionnaires.
CTRI NumberCTRI/2020/07/026667
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.25.22279181v1?rss=1
Authors: Raad, I., Hachem, R., Nigo, M., Datoguia, T., Dagher, H., Jiang, Y., Subbiah, V., Siddiqui, B., Bayle, A., Somer, R., Fernandez-Cruz, A., Gorak, E., Bhinder, A., Nobuyoshi, M., Hamerschlak, N., Shelanski, S., Dragovich, T., Kiat, Y. E. V., Fakhreddine, S., Hanna, P. A., Chemaly, R. F., Mulanovich, V., Adachi, J. A., Borjan, J., Khawaja, F., Granwehr, B., John, T., Guevara, E. Y., Torres, H., Ammakkanavar, N. R., Yibirin, M., Reyes, C., Pande, M., Ali, N., Rojo, R., Ali, S., Deeba, R., Chaftari, P., Matsuo, T., Ishikawa, K., Hasegawa, R., Aguado-Noya, R., Garcia, A. G., Puchol, C. T., Lee, D.-G
Abstract: BackgroundIn this international multicenter study we aimed to determine the independent risk factors associated with increased 30-day mortality and the impact of novel treatment modalities in a large group of cancer and non-cancer patients with COVID-19 from multiple countries.
MethodsWe retrospectively collected de-identified data on a cohort of cancer and non-cancer patients diagnosed with COVID-19 between January and November 2020, from 16 international centers.
ResultsWe analyzed 3966 COVID-19 confirmed patients, 1115 cancer and 2851 non-cancer patients. Cancer patients were more likely to be pancytopenic, and have a smoking history, pulmonary disorders, hypertension, diabetes mellitus, and corticosteroid use in the preceding two weeks (p less than or equal to 0.01). In addition, they were more likely to present with higher inflammatory biomarkers (D-dimer, ferritin and procalcitonin), but were less likely to present with clinical symptoms (p less than or equal to 0.01). By multivariable logistic regression analysis, cancer was an independent risk factor for 30-day mortality (OR 1.46; 95% CI 1.03 to 2.07; p=0.035). Older age ( greater than or equal to 65 years) was the strongest predictor of 30-day mortality in all patients (OR 4.55; 95% CI 3.34 to6.20; p less than 0.0001). Remdesivir was the only therapeutic agent independently associated with decreased 30-day mortality (OR 0.58; CI 0.39-0.88; p=0.009). Among patients on low-flow oxygen at admission, patients who received remdesivir had a lower 30-day mortality rate than those who did not (5.9% vs 17.6%; p=0.03).
ConclusionsCancer is an independent risk factor for increased 30-day all-cause mortality from COVID-19. Remdesivir, particularly in patients receiving low-flow oxygen, can reduce 30-day all-cause mortality.
Condensed AbstractIn this large multicenter worldwide study of 4015 patients with COVID-19 that included 1115 patients with cancer, we found that cancer is an independent risk factor for increased 30-day all-cause mortality. Remdesivir is a promising treatment modality to reduce 30-day all-cause mortality.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.24.22279177v1?rss=1
Authors: Mbrenga, F., Nakoune, E., Malaka, C., Bourner, J., Dunning, J., Vernet, G., Horby, P., Olliaro, P. L.
Abstract: BackgroundThere is currently no specific treatment recommended for monkeypox. This expanded access programme (EAP) aims to provide tecovirimat to patients with monkeypox and collect data on patient treatment, disease evolution and outcomes under a protocol to contribute to the evidence-base for the use of the drug for monkeypox.
MethodsPatients with confirmed monkeypox received tecovirimat according to the recommended dosing. Data on clinical signs and symptoms were recorded daily during treatment and at follow-up visits. Blood or lesion samples were taken during treatment and at day 28 to assess viral presence of monkeypox by PCR. As tecovirimat is administered via an EAP, outcome measures were not predefined. Adverse events and clinical outcomes were monitored by evaluating the total number and location of lesions, temperature, degree of incapacity, presence of adverse events, patient survival, and viral presence throughout treatment and follow-up.
ResultsWe report outcomes in 14 patients who were enrolled between December 2021 and February 2022. Muscle pain, headache, lymphadenopathy, lesions, fever, back pain, and upper respiratory symptoms were commonly reported at admission and during follow-up. The rate of appearance of active lesions gradually decreased throughout treatment, with the median time to no new lesions being 5 days following the start of treatment. No death attributable to monkeypox occurred in this cohort.
ConclusionsData collected through this EAP can help improve our knowledge about the use of tecovirimat for monkeypox. We have been able to document systematically the presentation and clinical and virological evolution of monkeypox under treatment.
Registration numberISRCTN43307947
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.26.22279242v1?rss=1
Authors: Mbamalu, O. N., Surendran, S., Nampoothiri, V., Bonaconsa, C., Edathadathil, F., Zhu, N., Carter, V., Lambert, H., Tarrant, C., Ahmad, R., Brink, A., Steenkamp, E., Holmes, A., Singh, S., Charani, E., Mendelson, M.
Abstract: A cross-sectional survey was performed among the adult population of participating countries, India and South Africa. The purpose of this study was to explore perceptions and awareness of SARS-CoV-2-related risks in the relevant countries. The main outcome measures were the proportion of participants aware of SARS-CoV-2, and their perception of infection risks.
Self-administered questionnaires were used to collect data via a web- and paper-based survey over three months. For data capturing, Microsoft Excel was employed, and descriptive statistics used for presenting data. Pearsons Chi-squared test was used to assess relationships between variables, and a p-value less than 0.05 was considered significant.
There were 844 respondents (India: n=660, South Africa: n=184; response rate 87.6%), with a 61.1% vs 38.3% female to male ratio. Post-high-school or university education was the lowest qualification reported by most respondents in India (77.3%) and South Africa (79.3%). Sources of information about the pandemic were usually media and journal publications (73.2%), social media (64.6%), family and friends (47.7%) and government websites (46.2%). Most respondents correctly identified infection prevention measures (such as physical distancing, mask use), with 90.0% reporting improved hand hygiene practices since the pandemic. Hesitancy or refusal to accept the SARS-CoV-2 vaccine was reported among 17.9% and 50.9% of respondents in India and South Africa, respectively. Reasons cited included rushed vaccine development and the futility of vaccines for what respondents considered a self-limiting flu-like illness.
Respondents identified public health promotion measures for SARS-CoV-2. Reported hesitancy to the up-take of SARS-CoV-2 vaccines was much higher in South Africa. Vaccination campaigns should consider robust public engagement and contextually fit communication strategies with multimodal, participatory online and offline initiatives to address public concerns, specifically towards vaccines developed for this pandemic and general vaccine hesitancy.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.25.22279238v1?rss=1
Authors: Peng, Z., Jimenez, J. L.
Abstract: The disinfection of air using Germicidal Ultraviolet light (GUV) is a long-standing technique, which has received intense attention during the COVID-19 pandemic. GUV generally uses UVC lamps as its light source, which are known to initiate photochemistry in air. However, the impact of GUV on indoor air quality and chemistry has not been investigated in detail, to our knowledge. In this study, we model the chemistry initiated by GUV at 254 or 222 nm ("GUV254" or "GUV222") in a typical room with typical indoor pollutant levels, and for different ventilation levels. GUV254 is irritating for skin and eyes, has an occupational exposure limit, and thus these fixtures typically irradiate a smaller volume near the ceiling, or inside ventilation ducts. In contrast, GUV222 is described by some as harmless to skin or eyes due to rapid absorption in a very thin external layer. Our analysis showed that GUV254 is able to significantly photolyze O3, generating OH radicals, which initiates the oxidation of all indoor volatile organic compounds (VOCs). While secondary organic aerosol (SOA) can be formed as a product of VOC oxidation, most of SOA in our case studies is produced through GUV-independent terpene ozonolysis. GUV254-induced SOA formation is of the order of 0.1-1 g m-3. GUV222 with the same effective virus removal rate makes a smaller impact on indoor air quality, mainly because of the significantly lower UV irradiance needed and substantially less efficient O3 photolysis (for primary OH generation) than at 254 nm.
SynopsisGermicidal ultraviolet at 254 nm initiates indoor oxidation chemistry, with limited impact under typical conditions. The impact of 222 nm germicidal UV disinfection is smaller.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer
Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2022.08.25.22279237v1?rss=1
Authors: Khoury, D. S., Docken, S. S., Subbarao, K., Kent, S., Davenport, M. P., Cromer, D.
Abstract: As a result of the emergence and circulation of antigenically distinct SARS-CoV-2 variants, a number of variant-modified COVID-19 vaccines have been developed. Here we perform a meta-analysis of the available data on neutralisation titres from clinical studies comparing booster vaccination with either the current ancestral-based vaccines or variant-modified vaccines. We then use this to predict the relative efficacies of these booster vaccines under different scenarios.
Copy rights belong to original authors. Visit the link for more info
Podcast created by PaperPlayer